Press Release

<< Back
Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in September 2017

BOSTON, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced it will webcast corporate presentations at the following investor conferences in September:

  • A fireside chat at Morgan Stanley’s Global Healthcare Conference in New York City on Tuesday, September 12, 2017 at 12:55 p.m. EDT.
  • Cantor Fitzgerald’s Global Healthcare Conference in New York City on Monday, September 25, 2017 at 4:45 p.m. EDT.
  • Ladenburg Thalmann’s 2017 Healthcare Conference in New York City on Tuesday, September 26 at 11:30 a.m. EDT.

Live audio webcasts of the presentations will be accessible from Keryx Biopharmaceuticals’ website at http://investors.keryx.com within the Investor Relations section under “webcasts and presentations.” An archived version of the webcast will be available for at least 15 days following the conclusion of the live presentations.

About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is a commercial stage company focused on bringing innovative medicines to people with kidney disease. Keryx developed and commercializes Auryxia® (ferric citrate) in the U.S. Ferric citrate is marketed as Riona® by Keryx’s Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex). Keryx has programs underway to leverage its development and commercial infrastructure, including potentially expanding the indication of Auryxia and in-licensing medicines for renal disease. For more information about Keryx, please visit www.keryx.com.

KERYX BIOPHARMACEUTICALS CONTACT:
Lora Pike
Senior Director, Investor Relations & Corporate Communications
T: 617-466-3511
lora.pike@keryx.com

Primary Logo

Keryx Biopharmaceuticals, Inc.